missing translation for 'onlineSavingsMsg'
Learn More
Learn More
DACT1 Monoclonal Antibody (OTI13H4), TrueMAB™, OriGene
Mouse Monoclonal Antibody
Brand: Origene Technologies TA809156S
This item is not returnable.
View return policy
Description
DACT1 Monoclonal antibody specifically detects DACT1 in Human samples. It is validated for Western BlotSpecifications
| DACT1 | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
| Q7Z5R6 | |
| Mouse | |
| Affinity chromatography | |
| RUO | |
| 54518 | |
| -20° C, Avoid Freeze/Thaw Cycles | |
| IgG1 |
| Western Blot | |
| OTI13H4 | |
| Unconjugated | |
| APBB1IP | |
| 4921528D17Rik; AI115603; dact1; dact1.S; dact1-a; dact1-b; DAPPER; dapper 1; dapper 1-A; dapper antagonist of catenin 1; Dapper homolog 1; dapper homolog 1, antagonist of beta-catenin; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antagonist of beta-catenin; dapper, antagonist of beta-catenin, homolog 1; dapper1; dapper1b; dishevelled binding antagonist of beta catenin 1; dishevelled-binding antagonist of beta-catenin 1; dishevelled-binding antagonist of beta-catenin 1 S homeolog; dishevelled-interacting protein; dpr; dpr1; frd1; FRODO; frodo 1; frodo homolog; Frodo1; functional regulator of dsh in ontogenesis; HDPR1; Hepatocellular carcinoma novel gene 3 protein; heptacellular carcinoma novel gene 3; HNG3; MDpr1; MTNG3; RGD1564008; signaling protein; thyex3; thymus expressed gene 3; thymus-expressed novel gene 3 protein; XDpr; XDpr1b; XELAEV_18041122mg | |
| Full length human recombinant protein of human APBB1IP produced in HEK293T cell. | |
| 30 μL | |
| Primary | |
| Human | |
| Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction